The Board of Directors of Alkem Laboratories is scheduled to meet on February 13, 2026, to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025 (Q3). The board will also consider approving an Interim Dividend for the financial year 2025-2026. The record date for the purpose of the interim dividend is set for February 20, 2026, subject to the board’s declaration.
Board Meeting Announcement
Alkem Laboratories has announced a meeting of its Board of Directors scheduled for February 13, 2026. During this meeting, the board will review key financial matters and consider important corporate actions.
Financial Results and Dividend
The primary agenda includes the consideration and approval of the Standalone and Consolidated Unaudited Financial Results for the third quarter (Q3) and nine months period ending December 31, 2025. Furthermore, the board will deliberate on the approval of an Interim Dividend for the financial year 2025-2026.
Interim Dividend Record Date
Subject to the declaration by the Board of Directors, the record date for determining shareholders eligible for the Interim Dividend is fixed as February 20, 2026.
Source: BSE
